Navtemadlin

Phase 3Small molecule

KKartos Therapeutics, Inc.

Navtemadlin is one of 237 small molecule programs targeting Brain Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

236

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain CancerActive, not recruiting

MyelofibrosisActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Endometrial CancerActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Brain CancerPhase 1

Active, not recruiting

MyelofibrosisPhase 3

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 1

Active, not recruiting

Endometrial CancerPhase 2/Phase 3

Active, not recruiting

Soft Tissue SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Navtemadlin

KKartos Therapeutics, Inc.

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

31 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 7

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

REGN2810

1 10

Huaier Granule

QQidong Gaitianli Medicines Co., Ltd

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2/3Recruiting

Endometrial Cancer

NCT05797831

Q4 2028

Phase 3Recruiting

Myelofibrosis

NCT06479135

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03041688·58 enrolled

Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04190550·24 enrolled

Multiple Myeloma1 trial

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03031730·35 enrolled

Myelofibrosis1 trial

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Recruiting·KKartos Therapeutics, Inc.·Phase 3·NCT06479135·600 enrolled

Combination Therapy1 trial

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Unknown status·TTelios Pharma, Inc.·Phase 1/2·NCT02825836·130 enrolled

Brain Cancer1 trial

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT03107780·32 enrolled

3 more indications

Non-Small Cell Lung Cancer1 trial

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Withdrawn·KKartos Therapeutics, Inc.·Phase 1/2·NCT05705466

Endometrial Cancer1 trial

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting·KKartos Therapeutics, Inc.·Phase 2/3·NCT05797831·268 enrolled

Soft Tissue Sarcoma1 trial

Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT03217266·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Navtemadlin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Navtemadlin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Navtemadlin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kartos Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: KKartos Therapeutics, Inc.

Navtemadlin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2028

Trials by Indication[1]

Acute Myeloid Leukemia2 trials

Multiple Myeloma1 trial

Myelofibrosis1 trial

Combination Therapy1 trial

Brain Cancer1 trial

Non-Small Cell Lung Cancer1 trial

Endometrial Cancer1 trial

Soft Tissue Sarcoma1 trial

References

Drug Info

Quick Facts

Related News